Baidu
map

J Arthroplasty:初次关节置换术后患者满意度的影响因素

2014-07-07 紫川秀第二 丁香园

髋、膝关节置换术是目前临床上最为成功的替代物置入手术,可以从很大程度上改善患者的疼痛和功能障碍。但是,随着置换关节使用年限的增加,假体松动,感染等事件概率发生呈现逐步上升趋势,患者满意度呈现下降趋势。 目前临床上尚缺乏对短期(2-5年)内关节置换术后满意度相关因素的研究,Lexington等人对此题目进行研究,结论发表于JOA杂志上。 研究者共收集1009例初次膝关节置换术的患者数据,包括膝关

髋、膝关节置换术是目前临床上最为成功的替代物置入手术,可以从很大程度上改善患者的疼痛和功能障碍。但是,随着置换关节使用年限的增加,假体松动,感染等事件概率发生呈现逐步上升趋势,患者满意度呈现下降趋势。

目前临床上尚缺乏对短期(2-5年)内关节置换术后满意度相关因素的研究,Lexington等人对此题目进行研究,结论发表于JOA杂志上。

研究者共收集1009例初次膝关节置换术的患者数据,包括膝关节功能评分,疼痛评分,关节主动运动度,患者满意度,再手术率,年龄,性别,BMI指数等。

研究结果发现,除去随访过程中死亡的23个TKA,剩余986例完成随访。其中27例患者最终需要再次手术(2.7%),15例是置换假体不稳定,5例膝关节僵直,4例是假体感染,2例是假体周围骨折,1例是胫骨假体轴线排列紊乱。

除外上述翻修术后的患者,并划定随访2-5年时间这一区间段,共纳入768例未行翻修的患者。总体不满意率为10.4%(80/768),患者满意率和术后膝关节疼痛(p<0.01),再手术率(p<0.01),膝关节功能评分(p<0.01)及膝关节主动运动度(p<0.01)等显著相关。而年龄,性别,BMI指数等指标和患者的满意度无显著相关性。

研究者通过上述数据发现,膝关节置换术后的患者不满意率(10.4%)要远大于膝关节再翻修率(2.7%),其中,再翻修最为多见的原因是关节不稳定和僵直。关节疼痛和关节主动运动度是TKA术后患者不满意的独立危险因素,这要求临床医生在进行手术治疗时需要充分的评估患者病情,同时在术前合理的制定手术方案,选择合适的假体型号,术中需仔细处理软组织平衡等,以减少术后可能影响患者运动,力学轴线和疼痛的各种因素。

原始出处:


Jacobs CA, Christensen CP.Factors influencing patient satisfaction two to five years after primary total knee arthroplasty.J Arthroplasty. 2014 Jun;29(6):1189-91. doi: 10.1016/j.arth.2014.01.008. Epub 2014 Jan 21.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1924782, encodeId=cf2a1924e82c7, content=<a href='/topic/show?id=5d87530552b' target=_blank style='color:#2F92EE;'>#患者满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53055, encryptionId=5d87530552b, topicName=患者满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Sep 21 11:31:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754142, encodeId=61421e541429b, content=<a href='/topic/show?id=7d3330135ac' target=_blank style='color:#2F92EE;'>#关节置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30135, encryptionId=7d3330135ac, topicName=关节置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=050736663344, createdName=apoenzyme, createdTime=Sun Apr 19 03:31:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710727, encodeId=c8f81e10727f2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 25 12:31:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742296, encodeId=fc781e4229651, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Sat Nov 15 08:31:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355883, encodeId=772d1355883d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465517, encodeId=de24146551ea5, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478631, encodeId=e2a414e8631e0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576490, encodeId=8e8f15e649080, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1924782, encodeId=cf2a1924e82c7, content=<a href='/topic/show?id=5d87530552b' target=_blank style='color:#2F92EE;'>#患者满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53055, encryptionId=5d87530552b, topicName=患者满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Sep 21 11:31:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754142, encodeId=61421e541429b, content=<a href='/topic/show?id=7d3330135ac' target=_blank style='color:#2F92EE;'>#关节置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30135, encryptionId=7d3330135ac, topicName=关节置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=050736663344, createdName=apoenzyme, createdTime=Sun Apr 19 03:31:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710727, encodeId=c8f81e10727f2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 25 12:31:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742296, encodeId=fc781e4229651, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Sat Nov 15 08:31:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355883, encodeId=772d1355883d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465517, encodeId=de24146551ea5, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478631, encodeId=e2a414e8631e0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576490, encodeId=8e8f15e649080, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1924782, encodeId=cf2a1924e82c7, content=<a href='/topic/show?id=5d87530552b' target=_blank style='color:#2F92EE;'>#患者满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53055, encryptionId=5d87530552b, topicName=患者满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Sep 21 11:31:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754142, encodeId=61421e541429b, content=<a href='/topic/show?id=7d3330135ac' target=_blank style='color:#2F92EE;'>#关节置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30135, encryptionId=7d3330135ac, topicName=关节置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=050736663344, createdName=apoenzyme, createdTime=Sun Apr 19 03:31:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710727, encodeId=c8f81e10727f2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 25 12:31:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742296, encodeId=fc781e4229651, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Sat Nov 15 08:31:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355883, encodeId=772d1355883d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465517, encodeId=de24146551ea5, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478631, encodeId=e2a414e8631e0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576490, encodeId=8e8f15e649080, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1924782, encodeId=cf2a1924e82c7, content=<a href='/topic/show?id=5d87530552b' target=_blank style='color:#2F92EE;'>#患者满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53055, encryptionId=5d87530552b, topicName=患者满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Sep 21 11:31:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754142, encodeId=61421e541429b, content=<a href='/topic/show?id=7d3330135ac' target=_blank style='color:#2F92EE;'>#关节置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30135, encryptionId=7d3330135ac, topicName=关节置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=050736663344, createdName=apoenzyme, createdTime=Sun Apr 19 03:31:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710727, encodeId=c8f81e10727f2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 25 12:31:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742296, encodeId=fc781e4229651, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Sat Nov 15 08:31:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355883, encodeId=772d1355883d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465517, encodeId=de24146551ea5, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478631, encodeId=e2a414e8631e0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576490, encodeId=8e8f15e649080, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
    2014-11-15 yxch48
  5. [GetPortalCommentsPageByObjectIdResponse(id=1924782, encodeId=cf2a1924e82c7, content=<a href='/topic/show?id=5d87530552b' target=_blank style='color:#2F92EE;'>#患者满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53055, encryptionId=5d87530552b, topicName=患者满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Sep 21 11:31:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754142, encodeId=61421e541429b, content=<a href='/topic/show?id=7d3330135ac' target=_blank style='color:#2F92EE;'>#关节置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30135, encryptionId=7d3330135ac, topicName=关节置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=050736663344, createdName=apoenzyme, createdTime=Sun Apr 19 03:31:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710727, encodeId=c8f81e10727f2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 25 12:31:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742296, encodeId=fc781e4229651, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Sat Nov 15 08:31:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355883, encodeId=772d1355883d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465517, encodeId=de24146551ea5, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478631, encodeId=e2a414e8631e0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576490, encodeId=8e8f15e649080, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
    2014-07-09 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1924782, encodeId=cf2a1924e82c7, content=<a href='/topic/show?id=5d87530552b' target=_blank style='color:#2F92EE;'>#患者满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53055, encryptionId=5d87530552b, topicName=患者满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Sep 21 11:31:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754142, encodeId=61421e541429b, content=<a href='/topic/show?id=7d3330135ac' target=_blank style='color:#2F92EE;'>#关节置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30135, encryptionId=7d3330135ac, topicName=关节置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=050736663344, createdName=apoenzyme, createdTime=Sun Apr 19 03:31:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710727, encodeId=c8f81e10727f2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 25 12:31:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742296, encodeId=fc781e4229651, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Sat Nov 15 08:31:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355883, encodeId=772d1355883d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465517, encodeId=de24146551ea5, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478631, encodeId=e2a414e8631e0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576490, encodeId=8e8f15e649080, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1924782, encodeId=cf2a1924e82c7, content=<a href='/topic/show?id=5d87530552b' target=_blank style='color:#2F92EE;'>#患者满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53055, encryptionId=5d87530552b, topicName=患者满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Sep 21 11:31:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754142, encodeId=61421e541429b, content=<a href='/topic/show?id=7d3330135ac' target=_blank style='color:#2F92EE;'>#关节置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30135, encryptionId=7d3330135ac, topicName=关节置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=050736663344, createdName=apoenzyme, createdTime=Sun Apr 19 03:31:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710727, encodeId=c8f81e10727f2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 25 12:31:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742296, encodeId=fc781e4229651, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Sat Nov 15 08:31:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355883, encodeId=772d1355883d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465517, encodeId=de24146551ea5, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478631, encodeId=e2a414e8631e0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576490, encodeId=8e8f15e649080, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1924782, encodeId=cf2a1924e82c7, content=<a href='/topic/show?id=5d87530552b' target=_blank style='color:#2F92EE;'>#患者满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53055, encryptionId=5d87530552b, topicName=患者满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=bugit, createdTime=Sun Sep 21 11:31:00 CST 2014, time=2014-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1754142, encodeId=61421e541429b, content=<a href='/topic/show?id=7d3330135ac' target=_blank style='color:#2F92EE;'>#关节置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30135, encryptionId=7d3330135ac, topicName=关节置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=050736663344, createdName=apoenzyme, createdTime=Sun Apr 19 03:31:00 CST 2015, time=2015-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1710727, encodeId=c8f81e10727f2, content=<a href='/topic/show?id=9a1c289680' target=_blank style='color:#2F92EE;'>#AST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2896, encryptionId=9a1c289680, topicName=AST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b9831894722, createdName=ms24272190615788285182, createdTime=Thu Sep 25 12:31:00 CST 2014, time=2014-09-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1742296, encodeId=fc781e4229651, content=<a href='/topic/show?id=39cae96626f' target=_blank style='color:#2F92EE;'>#置换#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79662, encryptionId=39cae96626f, topicName=置换)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3a7c35056336, createdName=yxch48, createdTime=Sat Nov 15 08:31:00 CST 2014, time=2014-11-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1355883, encodeId=772d1355883d1, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1465517, encodeId=de24146551ea5, content=<a href='/topic/show?id=144f5032688' target=_blank style='color:#2F92EE;'>#影响因素#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=50326, encryptionId=144f5032688, topicName=影响因素)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80a06745918, createdName=chenzhuanggui, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478631, encodeId=e2a414e8631e0, content=<a href='/topic/show?id=d561665e7af' target=_blank style='color:#2F92EE;'>#满意度#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66577, encryptionId=d561665e7af, topicName=满意度)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d1627448984, createdName=ms1692212821629096, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1576490, encodeId=8e8f15e649080, content=<a href='/topic/show?id=48fee966468' target=_blank style='color:#2F92EE;'>#置换术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79664, encryptionId=48fee966468, topicName=置换术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=054816326830, createdName=ms117281293605716, createdTime=Wed Jul 09 00:31:00 CST 2014, time=2014-07-09, status=1, ipAttribution=)]

相关资讯

JOT:如何提高骨科创伤患者满意度

患者的满意度,是衡量我们医疗质量优劣的重要因素。2007年以来,我国在医疗卫生行业中试点开展“两好一满意”活动,活动率先在山东开展,取得满意效果。这“一满意”,就是患者满意。由于我们面对的患者来自各个行业,性格各异,能让每个患者满意,确非易事。如何真正提高患者的满意度,是值得我们每一个医护人员思考的问题。【原文下载】 近来,美国学者Morris等进行了一项相关研究,值得我们学习借鉴。调查发现

Eur Spine J:患者的手术治疗决策权与术后满意度无关

提高患者的自主决策权被认为是改进医疗服务的重要一环。患者对治疗措施的决策权,依赖于当今医生为患者提供的信息越来越多。随着医患关系和共享决策权模式的发展,患者开始愿意积极参与他们的治疗措施的决策。然而,并非所有的患者都对自己成为治疗措施的决策者感到满意,或者想成为一名决策者。一些研究人员曾报道,参与程度本身(被动的,协同的,主动的)甚至会对实际决策产生负面影响。 以患者为中心的决策,会达成

Baidu
map
Baidu
map
Baidu
map